C12N 15/863
Poxviral vectors
Official title: Poxviral vectors, {e.g. entomopoxvirus}
C12N15/863 (Poxviral vectors) appears on 42 US grants and 52 published applications in this corpus.
Search patents in C12N- Granted patents
- 42
- Published applications
- 52
- Assignees
- 42
- Inventors
- 75
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 2 |
| 2011 | 0 | 2 |
| 2012 | 1 | 3 |
| 2013 | 1 | 5 |
| 2014 | 0 | 1 |
| 2015 | 7 | 3 |
| 2016 | 3 | 4 |
| 2017 | 3 | 6 |
| 2018 | 5 | 4 |
| 2019 | 2 | 4 |
| 2020 | 4 | 5 |
| 2021 | 4 | 1 |
| 2022 | 3 | 5 |
| 2023 | 3 | 1 |
| 2024 | 3 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Vaccines and uses thereof to induce an immune response to SARS-CoV217 Mar 2026US 12,577,589 B2GeoVax, Inc.
- Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)29 Jul 2025US 12,370,249 B2GeoVax, Inc.
- Chimpanzee adenoviral vector-based filovirus vaccines27 Feb 2024US 11,913,013 B2Sabin Vaccine Institute
- Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)13 Feb 2024US 11,896,657 B2GeoVax, Inc.
- Multivalent HIV vaccine boost compositions and methods of use13 Feb 2024US 11,897,919 B2GeoVax, Inc.
- Nucleic Acids Encoding TGF-Beta Inhibitor and IL-12 and Uses Thereof13 Aug 2026US 2026/0234667 A1KaliVir Immunotherapeutics, Inc.
- Recombinant hsv-1 vector for encoding immunostimulatory factor and anti-immune checkpoint antibody20 Nov 2025US 2025/0352619 A1Shanghai Ark Biopharmaceutical Co., Ltd.
- Replication-deficient modified vaccinia ankara (mva) expressing marburg virus glycoprotein (gp) and matrix protein (vp40)16 May 2024US 2024/0156940 A1GeoVax, Inc.
- Oncolytic vaccinia virus deficient in large region of genes16 Nov 2023US 2023/0364167 A1National University Corporation Tottori University
- Vaccines and uses thereof to induce an immune response to sars-cov215 Dec 2022US 2022/0396810 A1GeoVax, Inc.
Most cited
By later US patents
- Intrathecal and intratumoral superantigens to treat malignant disease18US 7,776,822 B2Jenquest · 2010
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites18US 9,133,480 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes15US 9,133,478 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Poxvirus expression system15US 9,273,327 B2Isis Innovation Limited · 2016
- Oncolytic virus for expression of immune checkpoint modulators9US 10,555,981 B2Transgene S.A. · 2020